General MedicationsINTRAVENOUSStandard

IBANDRONATE SODIUM

Standard Dose

EQ 3MG BASE/3ML

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview IBANDRONATE SODIUM is listed in Drugs@FDA under application 206058 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient IBANDRONATE SODIUM Form and strength INJECTABLE;INTRAVENOUS - EQ 3MG BASE/3ML Sponsor ACCORD HLTHCARE Submission history Latest submission status date: 2026-02-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview IBANDRONATE SODIUM is listed in Drugs@FDA under application 206058 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient IBANDRONATE SODIUM Form and strength INJECTABLE;INTRAVENOUS - EQ 3MG BASE/3ML Sponsor ACCORD HLTHCARE Submission history Latest submission status date: 2026-02-03 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.